Abstract
This chapter focuses on the neuroprotective properties of phytocannabinoids, beginning with a description of those cellular and molecular mechanisms and signaling pathways underlying these properties (e.g., control of glutamate homeostasis, calcium influx, toxicity of reactive oxygen species, glial activation, inflammatory events, and others). This is followed by descriptions of studies conducted with phytocannabinoids either in preclinical models of acute neurodegeneration, that focus particularly on ischemia, brain trauma, and spinal injury, or in preclinical models of certain chronic progressive neurodegenerative disorders, that focus particularly on Huntington’s chorea, Parkinson’s disease, Alzheimer’s disease, and amyotrophic lateral sclerosis. The chapter also discusses those neurodegenerative disorders that are presently being subjected to clinical phytocannabinoid research.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
